Researchers reviewed how the immune microenvironment surrounding tumors, known as the tumor immune microenvironment (TIME), affects bone health. The study focused on patients with osteosarcoma, a type of bone cancer. They looked at how specific immune cells like M2 TAMs, Tregs, and MDSCs create an environment that suppresses the body's natural defenses.
The review found that this specific immune environment can disrupt the balance of bone-building and bone-breaking processes. Specifically, it impacts the RANKL/RANK/OPG axis and osteoclast activity. This disruption leads to bone destruction, which increases the risk of pathological fractures for patients with osteosarcoma.
Because much of this evidence comes from laboratory models rather than large human clinical trials, these findings are currently theoretical. The results suggest a framework for future treatments that aim to balance the immune system while protecting bone integrity. Patients should discuss these emerging research concepts with their oncology team.